BioCentury
ARTICLE | Company News

Andrus Reo, Oncolytics deal

February 25, 2013 8:00 AM UTC

Oncolytics granted Andrus Reo rights in Russia and the Commonwealth of Independent States (CIS) to Reolysin. The formulation of human reovirus type 3 is in Phase III testing in head and neck cancer a...